{"id":38282,"date":"2025-11-11T13:39:48","date_gmt":"2025-11-11T06:39:48","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=38282"},"modified":"2025-11-11T13:39:48","modified_gmt":"2025-11-11T06:39:48","slug":"onward-therapeutics-completes-share-exchange-and-establishes-global-headquarters-in-taiwan-2","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=38282","title":{"rendered":"Onward Therapeutics Completes Share Exchange and Establishes Global Headquarters in Taiwan"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1438895\/Onward_Therapeutics_logo_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li>Following the group restructuring, Onward Therapeutics, Inc. serves as the global headquarters and holding company in <span class=\"xn-location\">Taiwan<\/span>.<\/li>\n<li>The existing Swiss and French subsidiaries maintain fully operational, focusing on preclinical and clinical development.<\/li>\n<li>All licenses, IP rights, and ongoing R&amp;D projects remain unchanged.<\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">TAIPEI<\/span> and LAUSANNE, <span class=\"xn-location\">Switzerland<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Nov. 11, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Onward Therapeutics today announced the completion of a share exchange, under which Onward Therapeutics, Inc. (Onward Taiwan) has become the group&#8217;s global holding and headquarters, while Onward Therapeutics\u00a0SA (Onward Switzerland) has become a wholly owned subsidiary of Onward Taiwan.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p>The group reorganization involved the exchange of all shares in the former Swiss parent company for shares in the new <span class=\"xn-location\">Taiwan<\/span> entity, maintaining ownership ratios and board composition. This milestone marks a strategic step in aligning Onward&#8217;s global operations and expanding its presence across <span class=\"xn-location\">Asia<\/span> and <span class=\"xn-location\">Europe<\/span>. The <span class=\"xn-location\">Taiwan<\/span> entity brings together Onward&#8217;s scientific and corporate teams across <span class=\"xn-location\">Taiwan<\/span>, <span class=\"xn-location\">Switzerland<\/span>, and <span class=\"xn-location\">France<\/span> under a unified corporate structure.<\/p>\n<p>Over the past six years, Onward has built a robust pipeline of four innovative programs targeting both solid and hematologic tumors, through in-licensing, acquisition, and internal discovery. The group reorganization was designed to align Onward&#8217;s corporate structure with <span class=\"xn-location\">Taiwan&#8217;s<\/span> dynamic biotechnology capital market and to support the company&#8217;s long-term growth plans, including future fundraising and potential public listing.<\/p>\n<p><span>Building on its strong base of Taiwanese and multinational shareholders, Onward aims to leverage <span class=\"xn-location\">Taiwan&#8217;s<\/span> scientific excellence, robust clinical trial infrastructure, and proven capabilities in advanced biopharmaceutical manufacturing to accelerate global development programs and partnerships. <span class=\"xn-location\">Taiwan&#8217;s<\/span> supportive regulatory framework and innovation-driven investment environment further reinforce <\/span><span>Onward&#8217;s<\/span><span> ability to pursue sustainable growth and its role as an international enterprise.<\/span><\/p>\n<p>Dr. C. <span class=\"xn-person\">Grace Yeh<\/span>, Founder, Chairperson and CEO of Onward Therapeutics, stated &#8220;I am very grateful for the unanimous approval of the share exchange by all shareholders. Establishing our global headquarters in <span class=\"xn-location\">Taiwan<\/span> represents both a symbolic and pragmatic achievement for Onward. <span class=\"xn-location\">Taiwan<\/span> combines innovation, efficiency, and connectivity, the essential elements for the next stage of our global growth. With an outstanding scientific community and a strong investor base, <span class=\"xn-location\">Taiwan<\/span> provides the ideal environment for Onward to expand its mission of developing transformative cancer therapies worldwide.&#8221;<\/p>\n<p><b>About Onward Therapeutics<\/b><\/p>\n<p>Onward Therapeutics (<a href=\"http:\/\/www.onward-therapeutics.com\/\" target=\"_blank\" rel=\"nofollow\">www.onward-therapeutics.com<\/a>) is a clinical-stage biotechnology company dedicated to overcoming cancer resistance with novel and multi-modality therapies. Led by a seasoned team in translational science and drug development, the company advances promising candidates through a fast-track development model. Its portfolio includes a bispecific antibody (OT-A201) licensed from Biomunex Pharmaceuticals, alongside an equity investment, and an allogeneic NK cell therapy (OT-C001) developed via its majority-owned subsidiary, Emercell. Beyond these two lead clinical assets, the company is developing two first-in-class early development programs, including a small molecule in onco-metabolism (OT-S00X) licensed from Institut du Cancer de Montpellier, and an internal multi-specific antibody platform (OT-A30X). Founded in <span class=\"xn-location\">Switzerland<\/span>, the company has established\u00a0its global headquarters in <span class=\"xn-location\">Taiwan<\/span>, reinforcing its integrated global operation across <span class=\"xn-location\">Taiwan<\/span>, <span class=\"xn-location\">Switzerland<\/span>, and <span class=\"xn-location\">France<\/span>.<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1438895\/Onward_Therapeutics_logo_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li>Following the group restructuring, Onward Therapeutics, Inc. serves as the global headquarters and holding company in <span class=\"xn-location\">Taiwan<\/span>.<\/li>\n<li>The existing Swiss and French subsidiaries maintain fully operational, focusing on preclinical and clinical development.<\/li>\n<li>All licenses, IP rights, and ongoing R&amp;D projects remain unchanged.<\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">TAIPEI<\/span> and LAUSANNE, <span class=\"xn-location\">Switzerland<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Nov. 11, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Onward Therapeutics today announced the completion of a share exchange, under which Onward Therapeutics, Inc. (Onward Taiwan) has become the group&#8217;s global holding and headquarters, while Onward Therapeutics\u00a0SA (Onward Switzerland) has become a wholly owned subsidiary of Onward Taiwan.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p>The group reorganization involved the exchange of all shares in the former Swiss parent company for shares in the new <span class=\"xn-location\">Taiwan<\/span> entity, maintaining ownership ratios and board composition. This milestone marks a strategic step in aligning Onward&#8217;s global operations and expanding its presence across <span class=\"xn-location\">Asia<\/span> and <span class=\"xn-location\">Europe<\/span>. The <span class=\"xn-location\">Taiwan<\/span> entity brings together Onward&#8217;s scientific and corporate teams across <span class=\"xn-location\">Taiwan<\/span>, <span class=\"xn-location\">Switzerland<\/span>, and <span class=\"xn-location\">France<\/span> under a unified corporate structure.<\/p>\n<p>Over the past six years, Onward has built a robust pipeline of four innovative programs targeting both solid and hematologic tumors, through in-licensing, acquisition, and internal discovery. The group reorganization was designed to align Onward&#8217;s corporate structure with <span class=\"xn-location\">Taiwan&#8217;s<\/span> dynamic biotechnology capital market and to support the company&#8217;s long-term growth plans, including future fundraising and potential public listing.<\/p>\n<p><span>Building on its strong base of Taiwanese and multinational shareholders, Onward aims to leverage <span class=\"xn-location\">Taiwan&#8217;s<\/span> scientific excellence, robust clinical trial infrastructure, and proven capabilities in advanced biopharmaceutical manufacturing to accelerate global development programs and partnerships. <span class=\"xn-location\">Taiwan&#8217;s<\/span> supportive regulatory framework and innovation-driven investment environment further reinforce <\/span><span>Onward&#8217;s<\/span><span> ability to pursue sustainable growth and its role as an international enterprise.<\/span><\/p>\n<p>Dr. C. <span class=\"xn-person\">Grace Yeh<\/span>, Founder, Chairperson and CEO of Onward Therapeutics, stated &#8220;I am very grateful for the unanimous approval of the share exchange by all shareholders. Establishing our global headquarters in <span class=\"xn-location\">Taiwan<\/span> represents both a symbolic and pragmatic achievement for Onward. <span class=\"xn-location\">Taiwan<\/span> combines innovation, efficiency, and connectivity, the essential elements for the next stage of our global growth. With an outstanding scientific community and a strong investor base, <span class=\"xn-location\">Taiwan<\/span> provides the ideal environment for Onward to expand its mission of developing transformative cancer therapies worldwide.&#8221;<\/p>\n<p><b>About Onward Therapeutics<\/b><\/p>\n<p>Onward Therapeutics (<a href=\"http:\/\/www.onward-therapeutics.com\/\" target=\"_blank\" rel=\"nofollow\">www.onward-therapeutics.com<\/a>) is a clinical-stage biotechnology company dedicated to overcoming cancer resistance with novel and multi-modality therapies. Led by a seasoned team in translational science and drug development, the company advances promising candidates through a fast-track development model. Its portfolio includes a bispecific antibody (OT-A201) licensed from Biomunex Pharmaceuticals, alongside an equity investment, and an allogeneic NK cell therapy (OT-C001) developed via its majority-owned subsidiary, Emercell. Beyond these two lead clinical assets, the company is developing two first-in-class early development programs, including a small molecule in onco-metabolism (OT-S00X) licensed from Institut du Cancer de Montpellier, and an internal multi-specific antibody platform (OT-A30X). Founded in <span class=\"xn-location\">Switzerland<\/span>, the company has established\u00a0its global headquarters in <span class=\"xn-location\">Taiwan<\/span>, reinforcing its integrated global operation across <span class=\"xn-location\">Taiwan<\/span>, <span class=\"xn-location\">Switzerland<\/span>, and <span class=\"xn-location\">France<\/span>.<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-38282","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/38282","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38282"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/38282\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38282"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38282"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38282"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}